Sfoglia per AUTORE
VALABREGA G
Collezione AO Ordine Mauriziano

  

Items : 39

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". in Future oncology (London, England) / Future Oncol. 2025 Jan;21(2):151-168. doi: 10.2217/fon-2023-0940. Epub 2024 Jul 11.
2025
AO Ordine Mauriziano

Mirza MR; Chase DM; Slomovitz BM; Christensen RD; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; et alii...

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review. in Pathogens (Basel, Switzerland) / Pathogens. 2025 Feb 3;14(2):140. doi: 10.3390/pathogens14020140.
2025
AO Ordine Mauriziano

Borella F; Carosso M; Chiparo MP; Ferraioli D; Bertero L; Gallio N; Preti M; Cusato J; Valabrega G; Revelli A; Marozio L; Cosma S;

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey. in Future oncology (London, England) / Future Oncol. 2025 Feb;21(4):437-445. doi: 10.1080/14796694.2025.2449782. Epub 2025 Jan 15.
2025
AO Ordine Mauriziano

Banerjee S; Eskander RN; Bailey T; Ambler W; Volpe S; Özgören O; Grabowski JP; Valabrega G;

Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification. in International journal of molecular sciences / Int J Mol Sci. 2024 Oct 24;25(21):11448. doi: 10.3390/ijms252111448.
2024
AO Ordine Mauriziano

Tuninetti V; Farolfi A; Rognone C; Montanari D; De Giorgi U; Valabrega G;

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Nov 2;74(1):6. doi: 10.1007/s00262-024-03860-w.
2024
AO Ordine Mauriziano

Galvagno F; Leuci V; Massa A; Donini C; Rotolo R; Capellero S; Proment A; Vitali L; Lombardi AM; Tuninetti V; D'Ambrosio L; Merlini A; Vigna E; Valabrega G; Primo L; Puliafito A; Sangiolo D;

Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights. in ESMO open / ESMO Open. 2024 Nov;9(11):103984. doi: 10.1016/j.esmoop.2024.103984. Epub 2024 Nov 13.
2024
AO Ordine Mauriziano

Ghisoni E; Valabrega G; Marín-Jiménez JA; Tuninetti V;

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5.
2024
AO Ordine Mauriziano

Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G;

Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30.
2024
AO Ordine Mauriziano

Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G;

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study. in Journal of clinical pathology / J Clin Pathol. 2024 Jun 19;77(7):478-485. doi: 10.1136/jcp-2023-208852.
2024
AO Ordine Mauriziano

Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A;

2024
AO Ordine Mauriziano

Makker V; Perez-Fidalgo JA; Valabrega G; Hamilton E; Van Gorp T; Sehouli J; Reginá?ová K; Richardson DL; Perri T; Oza AM; Miller DS; Alía EMG; De Giorgi U; Henry S; Spitz DL; Wimberger P; Bedna?íková M; Chon HS; Martínez-Garcia J; Pisano C; Berek JS; Romero I; Scambia G; Fariñas-Madrid L; Buscema J; Schochter F; Li K; Kalyanapu P; Walker CJ; et alii...

Response: Comment on searching for prognostic markers for stage I epithelial ovarian cancer: A role for systemic inflammatory markers. in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics / Int J Gynaecol Obstet. 2024 Jul;166(1):459-460. doi: 10.1002/ijgo.15595. Epub 2024 May 20.
2024
AO Ordine Mauriziano

Borella F; Bertero L; Valabrega G; Fucina S; Cassoni P; Benedetto C;

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications. in Current oncology (Toronto, Ont.) / Curr Oncol. 2024 Dec 20;31(12):8054-8074. doi: 10.3390/curroncol31120594.
2024
AO Ordine Mauriziano

Borella F; Fucina S; Seminara Y; Denti P; Ferraioli D; Bertero L; Gallio N; Cusato J; Valabrega G; Revelli A; Marozio L; Cosma S;

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. in Gynecologic oncology / Gynecol Oncol. 2024 Aug;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Epub 2024 Jun 3.
2024
AO Ordine Mauriziano

Valabrega G; Pothuri B; Oaknin A; Graybill WS; Sánchez AB; McCormick C; Baurain JF; Tinker AV; Denys H; O'Cearbhaill RE; Hietanen S; Moore RG; Knudsen AØ; de La Motte Rouge T; Heitz F; Levy T; York W; Gupta D; Monk BJ; González-Martín A;

Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. in Tumori / Tumori. 2023 Oct;109(5):490-495. doi: 10.1177/03008916221146820. Epub 2023 Jan 6.
2023
ASL Torino 5
AO Ordine Mauriziano

Artioli G; Valabrega G; Purro A; Mammoliti S; Testa S; Scotto G; Turinetto M; Bellero M; Milani A; Tuninetti V; Pignata S; Biglia N; Scandurra G; Mangili G; Di Maio M; De Giorgi U; Savarese A; Castaldo D; Lorusso D;

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. in Gynecologic oncology / Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
2023
AO Ordine Mauriziano

Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S;

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. in The New England journal of medicine / N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.
2023
AO Ordine Mauriziano

Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; et alii...

2023
AO Ordine Mauriziano

Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G;

2023
AO Ordine Mauriziano

Tuninetti V; Ghisoni E; Pignata S; Picardo E; Raspagliesi F; Andreetta C; Maldi E; Artioli G; Mammoliti S; Zanchi L; Sikokis A; Biglia N; Parisi A; Mandato VD; Carella C; Cormio G; Marinaccio M; Puppo A; Paolini B; Borsotti L; Scotto G; Turinetto M; Sangiolo D; Di Maio M; Valabrega G;

2023
AO Ordine Mauriziano

Turinetto M; Ricotti A; Marchetti C; Pisano C; Zamagni C; Cassani C; Malaguti P; Baldoni A; Scollo P; Scandurra G; Parisi A; Artioli G; Palaia I; Vertechy L; Bergamini A; Picardo E; Tuninetti V; Scotto G; Scambia G; Pignata S; Valabrega G;

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5.
2023
AO Ordine Mauriziano

Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; et alii...

2023
AO Ordine Mauriziano

Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S;

Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report. in Gynecologic oncology reports / Gynecol Oncol Rep. 2023 Jun 16;48:101220. doi: 10.1016/j.gore.2023.101220. eCollection 2023 Aug.
2023
AO Ordine Mauriziano

Zumstein L; Tuninetti V; Vaira M; Siatis D; Palermo F; Petracchini M; Scotto G; Turinetto M; Piva R; Pasini B; Valabrega G;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.
2023
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. in Cancer treatment reviews / Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24.
2022
AO Ordine Mauriziano

Musacchio L; Valsecchi AA; Salutari V; Valabrega G; Camarda F; Tuninetti V; Giannone G; Bartoletti M; Marchetti C; Pignata S; Fagotti A; Scambia G; Di Maio M; Lorusso D;

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). in British journal of cancer / Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.
2022
AO Ordine Mauriziano

Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S; et alii...

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? in International journal of molecular sciences / Int J Mol Sci. 2022 Mar 24;23(7):3559. doi: 10.3390/ijms23073559.
2022
AO Ordine Mauriziano

Turinetto M; Valsecchi AA; Tuninetti V; Scotto G; Borella F; Valabrega G;

2022
AO Ordine Mauriziano

Borella F; Cosma S; Ferraioli D; Ray-Coquard I; Chopin N; Meeus P; Cockenpot V; Valabrega G; Scotto G; Turinetto M; Biglia N; Fuso L; Mariani L; Franchi D; Vidal Urbinati AM; Pino I; Bertschy G; Preti M; Benedetto C; Castellano I; Cassoni P; Bertero L;

Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers. in Annals of surgical oncology / Ann Surg Oncol. 2022 Dec;29(13):8302-8314. doi: 10.1245/s10434-022-12353-y. Epub 2022 Aug 17.
2022
AO Ordine Mauriziano

Borella F; Cosma S; Ferraioli D; Ray-Coquard I; Chopin N; Meeus P; Cockenpot V; Valabrega G; Scotto G; Turinetto M; Biglia N; Fuso L; Mariani L; Franchi D; Vidal Urbinati AM; Pino I; Bertschy G; Preti M; Benedetto C; Castellano I; Cassoni P; Bertero L;

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. eCollection 2022.
2022
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.
2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14.
2021
AO Ordine Mauriziano

Peters S; Coukos G; Zimmermann S; Mederos Alfonso NN; Homicsko K; Obeid M; Aglietta M; Valabrega G; Marandino L; Tavazzi E; Gatta R; Pradervand S; Özdemir BC; Caikovski M; Latifyan S; Gautron Moura B; Gérard CL; Imbimbo M; Delyon J; Bouchaab H; Ghisoni E; Wicky A; Cuendet MA; Di Maio M; Michielin O;

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. in Gynecologic oncology / Gynecol Oncol. 2021 Jul;162(1):80-87. doi: 10.1016/j.ygyno.2021.04.018. Epub 2021 Apr 22.
2021
ASL VCO
AO Ordine Mauriziano

Valabrega G; Aglietta M; Pasini B; Di Maio M; Zavallone L; Gemmiti S; Turinetto M; Mittica G; Ghisoni E; Villa M; Tuninetti V; Mangiacotti S; Cosma S; Ferrero A; Borella F; Farolfi A; Katsaros D; De Giorgi U; Scotto G; Giannone G;

2020
AO Ordine Mauriziano

Tuninetti V; Di Napoli M; Ghisoni E; Maggiorotto F; Robella M; Scotto G; Giannone G; Turinetto M; Siatis D; Ponzone R; Vaira M; De Simone M; Scaffa C; Pignata S; Greggi S; Di Maio M; Valabrega G;

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. in In vivo (Athens, Greece) / In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
2019
AO Ordine Mauriziano

Mariniello A; Ghisoni E; Righi L; Catino A; Chiari R; Del Conte A; Barbieri F; Cecere F; Gelibter A; Giajlevra M; Parra HS; Zichi C; DI Maio M; Valabrega G; Novello S;

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. in Journal of ovarian research / J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6.
2019
AO Ordine Mauriziano

Ghisoni E; Maggiorotto F; Borella F; Mittica G; Genta S; Giannone G; Katsaros D; Sciarrillo A; Ferrero A; Sarotto I; Erriquez J; Di Renzo MF; Aglietta M; Valabrega G;

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. in Gynecologic oncology / Gynecol Oncol. 2015 Sep;138(3):627-33. doi: 10.1016/j.ygyno.2015.06.025. Epub 2015 Jun 20.
2015
AO Ordine Mauriziano

Valabrega G; Di Renzo MF; Aglietta M; Sapino A; Verdun di Cantogno L; Bruna P; Scalzo MS; Canuto EM; Maggiorotto F; Ferrero A; Ponzone R; Olivero M; Becco P; Erriquez J;

2008
AO Ordine Mauriziano

Montemurro F; Redana S; Nolè F; Donadio M; Jacomuzzzi ME; Valabrega G; Viale G; Sapino A; Aglietta M;